DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Physostigmine and cognition in schizotypal personality disorder.

Author(s): Kirrane RM, Mitropoulou V, Nunn M, Silverman J, Siever LJ.

Affiliation(s): Department of Psychiatry, Mount Sinai Medical Center, Bronx Veterans' Administration Medical Center, New York, NY, USA.

Publication date & source: 2001, Schizophr Res. , 48(1):1-5

There is evidence that reduced cholinergic activity may play a role in the pathophysiology of cognitive impairment in the schizophrenia spectrum. We tested the effects of physostigmine, an anticholinesterase inhibitor, on visuospatial working memory as evaluated by the Dot test, and on verbal learning and recall as measured by a serial learning task in patients with schizotypal personality disorder. Physostigmine tended to improve the Dot test, but not serial verbal learning performance in these patients.

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017